08:46 AM EDT, 08/08/2025 (MT Newswires) -- Nutriband ( NTRB ) said Friday that the US Food and Drug Administration has granted a Type C meeting to provide feedback on the chemistry, manufacturing and controls plans for Aversa fentanyl from the submission of investigational new drug application through commercialization.

The meeting is set to take place virtually on Sept. 18, the company said.

Nutriband ( NTRB ) is developing the patch in partnership with Kindeva combining its abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, the company said.

Shares of Nutriband ( NTRB ) were up 0.6% in recent Friday premarket activity.